Immunomedics (IMMU) Misses Q2 EPS by 50c

Immunomedics (NASDAQ: IMMU) reported Q2 EPS of ($0.84), $0.50 worse than the analyst estimate of ($0.34).

As of December 31, 2018, the Company had $497.8 million in cash, cash equivalents, and marketable securities, which it believes is adequate to support its clinical development plan for sacituzumab govitecan; further build its clinical and manufacturing infrastructure and fund its operations through 2020.

For earnings history and earnings-related data on Immunomedics (IMMU) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• UBS Upgrades Apollo Tyres (APTY:IN) to Buy
• The Buckle (BKE) Tops Q2 EPS by 7c, Beats on Revenue